Age-Related Maculopathy: A Genomewide Scan with Continued Evidence of Susceptibility Loci within the 1q31, 10q26, and 17q25 Regions  by Weeks, Daniel E. et al.
Am. J. Hum. Genet. 75:174–189, 2004
174
Age-Related Maculopathy: A Genomewide Scan with Continued Evidence
of Susceptibility Loci within the 1q31, 10q26, and 17q25 Regions
Daniel E. Weeks,1,2 Yvette P. Conley,1,3 Hui-Ju Tsai,1 Tammy S. Mah,4 Silke Schmidt,5
Eric A. Postel,6 Anita Agarwal,7 Jonathan L. Haines,8 Margaret A. Pericak-Vance,5
Philip J. Rosenfeld,9 T. Otis Paul,10 Andrew W. Eller,4 Lawrence S. Morse,11 J. P. Dailey,12
Robert E. Ferrell,1 and Michael B. Gorin1,4
Departments of 1Human Genetics and 2Biostatistics, University of Pittsburgh Graduate School of Public Health, 3University of Pittsburgh
School of Nursing, and 4Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh; 5Center for Human Genetics,
Department of Medicine, and 6Duke Eye Center, Department of Ophthalmology, Duke University Medical Center, Durham, NC; 7Department
of Ophthalmology and 8Center for Human Genetics Research, Vanderbilt University Medical Center, Nashville; 9Department of
Ophthalmology, University of Miami, Bascom Palmer Eye Institute, Miami; 10Smith-Kettlewell Eye Research Institute, San Francisco;
11Department of Ophthalmology, University of California–Davis, Davis, CA; and 12Department of Ophthalmology, Case Western Reserve
University, Cleveland
Age-related maculopathy (ARM), or age-related macular degeneration, is one of the most common causes of visual
impairment in the elderly population of developed nations. In a combined analysis of two previous genomewide
scans that included 391 families, containing up to 452 affected sib pairs, we found linkage evidence in four regions:
1q31, 9p13, 10q26, and 17q25. We now have added a third set of families and have performed an integrated
analysis incorporating 530 families and up to 736 affected sib pairs. Under three diagnostic models, we have
conducted linkage analyses using parametric (heterogeneity LOD [HLOD] scores under an autosomal dominant
model) and nonparametric (Sall statistic) methods. There is ongoing evidence of susceptibility loci within the 1q31,
10q26, and 17q25 regions. If we treat the third set of families as a replication set, then two regions (10q26 and
17q25) are replicated, with LOD scores 11.0. If we pool all our data together, then four regions (1q31, 2q14.3,
10q26, and 17q25) show HLOD or Sall scores 2.0. Within the 1q31 region, we observed an HLOD of 2.72
(genomewide ) under our least stringent diagnostic model, whereas the 17q25 region contained a maximalPp .061
HLOD of 3.53 (genomewide ) under our intermediate diagnostic model. We have evaluated our resultsPp .007
with respect to the ﬁndings from several new independent genomewide linkage studies and also have completed
ordered subset analyses (OSAs) with apolipoprotein E alleles, smoking history, and age at onset as stratifying
covariates. The OSAs generate the interesting hypothesis that the effect of smoking on the risk of ARM is accentuated
by a gene in the 10q26 region—a region implicated by four other studies.
Introduction
Age-related maculopathy (ARM), or age-related macu-
lar degeneration (ARMD1 [MIM 603075]), is one of the
most common causes of visual impairment in the elderly
within developed nations. The condition affects nearly
10% of those 165 years of age and affects 125% of
those 175 years of age (for a review, see Gorin [1998]).
The medical costs for the evaluation and treatment of
ARM complications are considerable and increase with
more severe disease (Bonastre et al. 2003). Treatment
has focused primarily on the choroidal neovasculariza-
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tion that is a complication of the condition, though only
a relatively small percentage of patients currently beneﬁt
from existing therapies (Mandal and Chisholm 2002;
Hooper and Guymer 2003). Strategies to reduce the pro-
gression of the condition, such as the intake of vitamin,
mineral, and antioxidant supplements, have been shown
to be effective (Age-Related Eye Disease Study Research
Group 2001) but still are limited predominantly to pa-
tients with clinical evidence of the disease. There is com-
pelling evidence of a genetic risk of ARM from epi-
demiologic studies, as well as from twin studies and
segregation analyses (for a review, see Gorin [1998]).
There is a growing impetus for these genetic studies not
only to identify the biological bases for this complex
disorder but to improve preventive approaches by pro-
viding a means of identifying, prior to the onset of clin-
ical ﬁndings, individuals at high risk of developing the
condition.
Several genetic approaches have been undertaken to
study ARM. One strategy has been to screen those genes
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(Mb) HLOD log10 (P) Sall Citation
1:
D1S1589 1q24 192.1 171.5 2.41 … … Seddon et al. 2003
HEMICENTIN-1 1q25.3–1q31.1 … 182.9 … … … Schultz et al. 2003a, 2003c
D1S202 1q31 201.6 184.2 … 2.89 … Iyengar et al. 2004
D1S518 1q31 202.2 184.8 2.07 … … Majewski et al. 2003
D1S1660 1q31 212.4 195.9 … 1.00 … Seddon et al. 2003
D1S1660 1q31 212.4 195.9 2.46 … … Weeks et al. 2001
D1S413 1q31 212.4 195.9 3.00a … … Klein et al. 1998
D1S549 1q41 239.7 216.7 … … 2.13 Abecasis et al. 2004
2:
D2S1780 2p25.3 10.0 3.3 … … 1.96 Abecasis et al. 2004
D2S1356 2p21 64.3 43.3 … 2.39 … Iyengar et al. 2004
D2S1384 2q33 200.4 205.4 2.37 1.40 … Seddon et al. 2003
3:
D3S1304 3p13 22.3 6.9 2.19 … … Majewski et al. 2003
D3S1763 3q26.1 176.5 168.6 … 2.09 … Schick et al. 2003
4:
D4S3360 4p16 .0 .1 … 2.06 … Iyengar et al. 2004
D4S2368 4q32 167.6 169.4 2.66 … … Majewski et al. 2003
5:
D5S814 5p14.1 39.5 25.9 … … 1.72 Abecasis et al. 2004
D5S1506 5p13.3 49.5 33.9 … … 2.55 Abecasis et al. 2004
D5S2500 5q12–5q13 69.2 58.7 … 1.42 … Schick et al. 2003
D5S1456 5q34 174.8 169.0 … 2.31 … Iyengar et al. 2004
6:
D6S1031 6q14–6q21 88.6 77.5 … 1.38 … Schick et al. 2003
D6S2436 6q23–6q24 154.6 154.2 … 1.54 … Schick et al. 2003
9:
D9S1871 9p24 8.4 3.8 … 2.32 … Iyengar et al. 2004
D9S1118 9p13 58.3 31.9 1.79 … … Weeks et al. 2001
D9S938 9q31 110.9 101.4 … 2.10 … Iyengar et al. 2004
D9S938 9q31.1 110.9 101.4 … … 1.65 Abecasis et al. 2004
D9S934 9q33 128.0 116.5 … … 2.01 Majewski et al. 2003
10:
D10S1230 10q26 142.8 122.4 3.06 … … Majewski et al. 2003
D10S1230 10q26 142.8 122.4 2.00 … … Weeks et al. 2001
D10S1230 10q26 142.8 122.4 1.52 … … Kenealy et al. 2004
D10S1222 10q26 156.3 128.7 1.90 1.30 … Seddon et al. 2003
D10S1248 10q26 165.3 130.6 … 2.43 … Iyengar et al. 2004
12:
D12S297 12q13 65.0 50.9 … 2.18 … Iyengar et al. 2004
D12S1300 12q23–12q24 … 97.0 … 2.20 … Schick et al. 2003
PAH 12q22–12q23 … 101.7 … 1.45 … Schick et al. 2003
D12S2078 12q23 … 126.3 … 2.70 … Iyengar et al. 2004
15:
GATA50C03 15q14 34.8 34.7 … 5.00 … Iyengar et al. 2004
D15S659 15q11.1–15q14 43.5 44.1 … 1.32 … Schick et al. 2003
D15S816 15q25–15q26 100.6 92.7 … 1.35 … Schick et al. 2003
16:
D16S769 16p12.1 50.6 26.1 … 1.92 … Iyengar et al. 2004
D16S769 16p12.1 50.6 26.1 … 2.07 … Schick et al. 2003
17:
D17S928 17q25 126.5 80.9 3.16 … … Weeks et al. 2001
18:
GATA178F11 18p11 … 2.1 … 2.48 … Iyengar et al. 2004
20:
D20S451 20q13 … 57.3 … 2.28 … Iyengar et al. 2004
22:
AGAT055Z 22q12.1 … 25.8 … … 2.03 Abecasis et al. 2004
D22S683 22q12–13 36.2 34.8 .94 2.00 … Seddon et al. 2003
a Parametric LOD score in a single large family.
which are known to be causative for the monogenic
juvenile macular dystrophies, such as Best disease
(VMD [MIM 153700], VMD2 [MIM 607854]); Star-
gardt disease (STGD1 [MIM 248200], ABCA4 [MIM
601691]); malattia leventinese (MLVT [MIM 126600],
EFEMPI [MIM 601548]); autosomal dominant Star-
gardt-like dystrophy (STGD3 [MIM 600110], ELOVL4
[MIM 605512]); cone dystrophy (CORDX1 [MIM
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MGS CIDR1 CIDR2 All MGS CIDR1 CIDR2 All MGS CIDR1 CIDR2 All
Families with 2 genotyped affected
members
132 132 152 416 136 136 156 428 163 165 202 530
Affected individuals 376 328 395 1,099 399 357 415 1,171 457 415 501 1,373
Genotyped affected individuals 347 322 386 1,055 351 341 397 1,089 401 392 481 1,274
Genotyped affected pairs:
Sibling 135 151 174 460 157 177 197 531 210 229 297 736
Half-sibling 5 0 0 5 6 0 1 7 6 4 2 12
Avuncular 18 9 9 36 19 11 10 40 29 22 19 70
Cousin 29 15 12 56 29 21 13 63 37 26 20 83
Half-avuncular 0 0 1 1 2 0 1 3 2 0 2 4
Great-avuncular 0 0 0 0 2 0 0 2 3 0 0 3
Parental 1 2 4 7 5 3 4 12 13 8 10 31
Grandparental 0 0 0 0 0 0 0 0 0 0 2 2
304020], RPGR [MIM 312610]); adult vitelliform dys-
trophy (AVMD [MIM 608161], RDS [MIM 179605]);
and Sorsby fundus dystrophy (SFD [MIM 136900],
TIMP3 [MIM 188826]). At this time, none of these
genes appear to be responsible for a signiﬁcant per-
centage of ARM cases (Weeks et al. 2000, 2001; Stone
et al. 2001), though certainly they may contribute to a
fraction of the ARM population. A number of candidate
genes also have been investigated on the basis of their
role in retinal physiology and/or retinal pigment epi-
thelium physiology, and, yet again, there has been little
evidence of a major role for any of these genes in the
etiology of ARM (Stone et al. 1998, 2001; Weeks et al.
2000, 2001). Apolipoprotein E (APOE [MIM 107741])
alleles have been shown to contribute signiﬁcantly to
the risk of several medical conditions, including Alz-
heimer disease (AD2 [MIM 104310]) (Corder et al.
1994; Breitner et al. 1998;Meyer et al. 1998). A number
of studies have provided fairly consistent evidence that
the APOE-4 allele appears to be partially protective
against ARM, whereas the APOE-2 allele may increase
risk (but this has been shown less consistently) (Klaver
et al. 1998; Souied et al. 1998; Pang et al. 2000; Schmidt
et al. 2002; Schultz et al. 2003b).
Another genetic approach to investigating a complex
genetic disorder, such as ARM, has been to use small
families with the disorder to look for genomic regions
that are shared in common, among two or more affected
relatives, more frequently than is predicted by chance.
Such an approach is relatively robust in dealing with
the genetic heterogeneity of ARM and is independent
from the biological hypotheses that have guided pure
candidate gene studies. We have performed two ge-
nomewide scans the results of which are published else-
where (Weeks et al. 2000, 2001). When we analyzed
these together, in a combined analysis of 391 families
containing up to 452 affected sib pairs, we found evi-
dence of linkage in four regions: 1q31, 9p13, 10q26,
and 17q25 (table 1). The locus on chromosome 1q31
independently conﬁrmed a report by Klein et al. (1998),
which mapped an ARM susceptibility gene to this
region.
Using a quantitative measure of ARM severity as the
phenotype, Schick et al. (2003) performed a genome-
wide scan of 102 families from the Beaver Dam eye
study, with model-free methods. This method most
strongly implicated a region on chromosome 12q23–24
(near D12S346) and also implicated regions on chro-
mosomes 5q12–13, 6q14–21, 15q11–14, and 15q25–
26 (table 1).
Using a qualitative ARM phenotype on 70 large fam-
ilies, Majewski et al. (2003) used parametric and allele-
sharing models to perform a genomewide scan. Their
study found evidence for linkage in ﬁve regions—1q31,
3p13, 4q32, 9q33, and 10q26 (table 1)—in addition to
ﬁnding another large family that, by itself, maps to
1q25–31 with a LOD score of 2.59.
Seddon et al. (2003) performed a genomewide scan
of 158 families, using a qualitative ARM phenotype. In
their study, there were 490 affected individuals, and 101
individuals were coded as “unaffected” because they
were 60 years old and had no evidence of AMD or
minimal maculopathy. Using parametric andmodel-free
methods, Seddon et al. found evidence for linkage on
10 different chromosomes, including the regions 1q24,
2q33, 10q26, and 22q12–13 (table 1).
Using a quantitative phenotype based on ARM sever-
ity, Iyengar et al. (2004) performed a genomewide scan
of 34 extended pedigrees with model-free methods. Their
strongest linkage signal was seen in the 15q14 region,
and they also observed 13 regions on 11 chromosomes
containing nominal evidence of linkage (table 1).
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Abecasis et al. (2004) performed a 5-cM genomewide
scan of 412 affected relative pairs, using nonparametric
linkage analyses with two different diagnostic criteria.
They found linkage in 5 regions: 1q41, 2p25, 5p13–
14, 9q31, and 22q12 (table 1).
The studies to date are quite encouraging in their
consistency—there are two regions (1q25–31 and
10q26) that have been implicated in ARM by multiple
studies (table 1). The 1q25–31 region has been impli-
cated by the results of ﬁve studies to date: a LOD score
of 3 in one large family (Klein et al. 1998); our conﬁr-
mation, with linkage to exactly the same position
(Weeks et al. 2001); and further evidence of linkage in
an expanded set of large families (Majewski et al. 2003),
as well as in two other independent sets of families
(Seddon et al. 2003; Iyengar et al. 2004). Abecasis et
al. (2004) also found a linkage signal nearby in 1q41,
which may be interpreted as implicating the same gen-
eral region. Furthermore, a mutation in the HEMICEN-
TIN gene (also known as “FIBULIN 6” [FIBL6 (MIM
608548)]) has been found that segregates with the dis-
ease in the initial large family (Schultz et al. 2003a).
Additional evidence supporting this HEMICENTIN
mutation is the identiﬁcation of the mutation in a few
other independent families with ARM, all of whom
seem to share a common haplotype (Schultz et al.
2003c). HEMICENTIN is structurally related to the
EFEMP1 gene, which has been implicated in malattia
leventinese, a monogenic macular dystrophy (Stone et
al. 1999). Conﬁrmation of the role of the HEMICEN-
TIN-1 gene by other ARM research groups is still pend-
ing at this time.
The 10q26 region has been implicated in ARM stud-
ies multiple times (table 1). Our ﬁrst genomewide scan
had its maximum multipoint Sall score of 1.42 near
D10S1236 (Weeks et al. 2000); in our second paper,
an Sall peak was seen consistently across all three di-
agnostic models, with a maximum Sall of 2.10 between
D10S1237 and D10S1230 under model A (our strictest
model) (Weeks et al. 2001). Similarly, Majewski et al.
(2003) found their strongest evidence of linkage at
D10S1230. Also, Seddon et al. (2003) observed a max-
imized heterogeneity LOD score (HLOD) of 1.90 in the
10q26 region at D10S1222, ∼13 cM from D10S1230.
Iyengar et al. (2004) obtained a log10(P) of 2.43 in
the 10q26 region. Kenealy et al. (2004) obtained an
HLOD of 1.52 and an MLS score of 1.52 at D10S1230
in 10q26, using 70 multiplex families containing 133
affected sib pairs.
Here, we present the results of a genome scan on a
third set of families, extending our previous work
(Weeks et al. 2000, 2001). We examine the implications
of treating this third set as a replication data set, as well
as examining the results when we simply pool all three
of our genome scans together in one large data set—
this combined data set is the largest number of families
with ARM analyzed together to date. We also perform
exploratory data analyses, using the ordered subset
analysis (OSA) approach (Hauser and Boehnke 1998;
Ghosh et al. 1999, 2000; Watanabe et al. 1999; Hauser
et al. 2001, 2004), which attempts to improve genetic
homogeneity by examining subsets of the data where
families are included on the basis of relevant covariates.
Material and Methods
Families
The families in the University of Pittsburgh cohort
were ascertained from a pool of 35,000 individuals, pre-
sumed to be affected by ARM, by a combination of
approaches, including recruitment of families from
within the retina service of the Department of Oph-
thalmology at the University of Pittsburgh and mailings
sent to patients with ARM (on the basis of billing ICD-
9 codes) from multiple retina and ophthalmic practices
across the United States (Weeks et al. 2000, 2001). Pa-
tients who were interested in participating in the study
forwarded a self-addressed postcard to the investigators
so that they could be contacted by phone and mail.
Through the initial family members, other family mem-
bers were informed of the study and encouraged to par-
ticipate. The informed consent process was approved by
the institutional review board of the University of Pitts-
burgh. The families with ARM in the Duke University
and Vanderbilt University cohorts were selected for the
disease in a similar fashion to that used by Weeks et al.
(2000, 2001). Probands were identiﬁed from the retina
services of each institution, and family members were
brought to the examination centers for standardized
clinical evaluations and fundus photographs. Families
were genotyped in three different sets (see below for
details); table 2 shows the number of families included
at each of the three genotyping stages.
Documentation of the retinal features and other oc-
ular pathology were obtained from direct clinical ex-
aminations (of local subjects when possible), eye care
records (from all eye care providers), and fundus pho-
tographs. Every effort was made to document the pres-
ence or absence of drusen; the type, size, number, and
conﬂuence of drusen; the presence of pigment epithelial
ﬁgures; choroidal neovascular membranes; geographic
atrophy; pigment epithelial detachments (both serous
and drusenoid); pigment epithelial tears; and laser treat-
ments (for choroidal neovascular membranes). Other
ocular pathology and surgery, including potential con-
founding diagnoses, were also recorded.
Table 3












CombinedCombined MGS CIDR1 CIDR2 Combined MGS CIDR1 CIDR2
A:
1:
D1S1660a 228.7 .35 .03 .90 .00 1.89 .45 .08 .85 .00 .72
D1S1647a 232.3 1.07 NA .95 .25 1.87 .20 NA .45 .00 .61
D1S1678a 234.9 .16 .16 NA NA 1.78 .05 .05 NA NA .56
2:
D2S1328a 141.7 .71 .01 1.44 .02 .43 3.23 .96 2.71 .25 2.42
3:
D3S4523 145.3 1.44 .25 .16 1.26 .85 2.14 .27 .28 2.06 1.78
4:
D4S2367 71.9 .48 .68 .26 .00 1.28 1.11 .03 .72 .70 1.57
D4S1644 144.4 .16 .35 .00 .01 .21 1.63 .12 .66 1.14 1.70
7:
D7S1808 37.5 2.00 .57 .04 1.97 1.86 .92 .07 .00 1.85 1.24
10:
D10S1230a 151.8 1.58 1.15 .39 .20 .87 2.45 1.55 .82 .38 2.32
14:
D14S599a 31.6 1.21 .12 1.02 .36 .81 2.58 .66 1.02 .98 1.82
D14S306 35.1 .19 .00 .44 .23 .87 .84 .00 .64 .59 1.86
16:
ATA41E04a .0 1.50 .17 1.52 .32 .73 1.69 1.59 .43 .15 .82
17:
D17S784a 128.8 1.41 .01 1.45 .62 2.54 .57 .03 .94 .06 .78
D17S928a 139.3 .83 .20 .78 .04 2.19 .03 .00 .42 .00 .36
B:
1:
D1S1660a 228.7 .68 .14 .95 .00 1.71 .85 .29 .86 .00 1.06
D1S1647a 232.3 .73 NA .51 .25 1.74 .23 NA .21 .06 .91
D1S1678a 234.9 .70 .33 NA NA 1.64 .28 .28 NA NA .85
2:
D2S1328a 141.7 .48 .03 .88 .00 .15 2.18 .58 2.11 .13 1.35
3:
D3S2460 141.8 .50 .22 .00 .88 .76 1.07 .09 .00 1.78 1.53
D3S4523 145.3 1.50 .18 .18 1.53 .57 1.88 .23 .07 2.39 1.52
4:
D4S2367a 71.9 1.02 1.58 .32 .00 1.12 1.07 .10 .75 .45 1.55
D4S2394 129.2 1.13 .00 .00 .45 .20 1.04 .03 .48 .71 1.50
D4S1644 144.4 .07 .41 .00 .02 .31 1.14 .15 .23 .94 1.61
6:
D6S2427 49.9 .74 .05 .92 .09 1.26 .69 .01 1.06 .17 1.76
7:
D7S1808 37.5 1.47 .85 .00 1.36 1.93 .46 .03 .00 1.32 .83
10:
D10S1230a 151.8 1.07 1.20 .09 .11 .62 1.84 1.56 .16 .46 1.97
D10S1213 157.4 .57 .24 .36 NA .75 .54 .32 .22 NA 1.58
D10S1656 158.5 .00 NA NA .00 .68 .28 NA NA .28 1.51
14:
D14S599a 31.6 1.01 .26 1.02 .06 .40 2.52 1.08 .74 .71 1.65
17:
D17S784a 128.8 2.05 .16 1.15 1.02 3.42 .71 .22 .36 .16 .71
D17S928a 139.3 1.52 .58 1.11 .06 3.23 .07 .09 .13 .00 .45
(continued)













CombinedCombined MGS CIDR1 CIDR2 Combined MGS CIDR1 CIDR2
C:
1:
D1S518a 217.4 1.95 .42 1.27 .47 1.80 1.65 .53 1.06 .25 1.89
D1S1660a 228.7 .91 .02 .75 .50 2.72 1.28 .31 .89 .19 1.83
D1S1647a 232.3 1.72 NA .49 1.34 2.36 .65 NA .10 .63 1.44
D1S1678a 234.9 .01 .01 NA NA 2.11 .01 .01 NA NA 1.28
D1S2141 250.9 1.59 .66 .21 .77 .93 .70 .08 .01 1.10 .69
3:
D3S2432 57.9 .00 .00 .00 .04 .00 1.45 .56 .11 .98 1.67
D3S1768 61.6 1.26 .56 .48 .24 .06 1.42 .07 .32 1.51 1.56
D3S1766 80.2 .11 .00 .00 .59 .06 1.69 .32 .01 2.17 1.41
4:
D4S2367a 71.9 1.00 1.51 .36 .00 .93 1.34 .16 1.37 .28 1.61
D4S1644 144.4 .56 1.15 .00 .02 .79 .99 .45 .33 .24 1.56
10:
D10S1230a 151.8 1.91 .52 .77 .65 .59 2.74 1.11 .61 1.03 2.69
D10S1213 157.4 .79 .34 .47 NA .63 1.12 .92 .28 NA 2.24
D10S1656 158.5 .00 NA NA .00 .56 .30 NA NA .30 2.09
12:
D12S2070a 131.5 .07 .46 .00 .00 .48 .70 .63 .19 .05 1.63
14:
D14S599a 31.6 2.38 .82 .57 1.01 .52 3.15 1.70 .53 1.04 1.78
16:
ATA41E04 .00 .96 .06 .72 .39 .29 1.58 .62 .42 .55 .88
17:
D17S784a 128.8 1.33 .25 .56 .56 2.52 .29 .25 .17 .00 .49
D17S928a 139.3 1.56 .84 1.63 .00 2.92 .04 .30 .21 .00 .40
NOTE.—Markers are displayed if they have a single-point Sall or HLOD score 1.5 on the combined data set or have a multipoint Sall or
HLOD score 1.5 at the marker (underlined values). The cM positions do not agree exactly with those in table 1, because this table uses
Haldane cM, whereas table 1 uses Kosambi cM; however, the proper recombination fractions were used in all analyses.
a Marker that appeared in the comparable table in our report published elsewhere (Weeks et al. 2001).
Evaluations
Clinical records were evaluated separately from fun-
dus photographs by a single investigator (M.B.G.), and
evaluations were done in separate sessions. Prior to re-
view, each fundus photographwasmaskedwith a unique
series of letters and numbers by the clinical coordinating
staff to conceal the identity of the individual. As original
eye records, which often cannot be masked, were ob-
tained, these were graded separately and then were com-
pared with the photographs to reconcile discrepancies
and determine a ﬁnal grade. If the documentation was
insufﬁcient to clearly characterize the individual’s con-
dition, additional records and/or photographs were
sought. In the cases from Vanderbilt and Duke, the clin-
ical records and fundus photographs were reviewed by
a single investigator (M.B.G.) on separate days and then
were reconciled. With only a few exceptions, the indi-
vidual grading classiﬁcations (affected, probably af-
fected, and possibly affected or unknown) were the same
for clinical investigators from Duke (E.A.P.) and Van-
derbilt (A.A.) and for M.B.G. Among the clinical inves-
tigators, there were no discrepancies in the diagnoses of
ARM. Of the total 1,616 individuals submitted for ge-
notyping in any or all of the three genomewide scans,
1,177 individuals had photographs and 1,560 individ-
uals had records. There were 415 individuals who had
only records available and 46who had only photographs
available.
Genotyping Methods
Genomic DNA was extracted from leukocytes ob-
tained fromwhole blood collected into EDTA vacutainer
tubes. The samples from the University of Pittsburgh
were extracted with the use of a simple salting-out pro-
cedure, as described elsewhere (Miller et al. 1988), and
the samples from our collaborators at Duke and Van-
derbilt Universities were extracted with the use of the
Puregene DNA puriﬁcation method (Gentra Systems).
The samples were diluted in 1 times TE buffer and sent
as coded aliquots either to the National Heart, Lung,
180
Figure 1 The multipoint HLOD (solid line) and the multipoint nonparametric Sall (dashed line) for chromosomes 1, 2, 10, and 17. Note
that some of the marker names are not displayed because of resolution limitations.
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No. of Families Used/





7 37.5 D7S1808 A 1.216 3.179 370/562 73.00 .0110 LrH
8 21.9 D8S1130 A .014 3.455 61/563 [59.00, 63.50] .0429 S
8 23.3 D8S1130 B .001 4.086 60/567 [59.00, 63.50] .0058 S
8 13.3 D8S1469 C .108 2.828 137/573 65.75 .0112 LrH
8 13.3 D8S1469 C .108 4.411 101/573 [59.00, 65.75] .0040 S
12 12.6 D12S2395 A .639 3.393 237/564 69.00 .0243 LrH
12 12.6 D12S2395 B .672 3.449 240/568 69.00 .0345 LrH
19 46.5 D19S433 C .098 1.851 209/571 72.67 .0419 HrL
a L p low; H p high; S p optimal slice method.
and Blood Institute (NHLBI) Mammalian Genotyping
Service (MGS) or to the Center for Inherited Disease
Research (CIDR) (supported by the National Institutes
of Health [NIH], including the National Eye Institute).
Both genotyping centers use primarily tri- and tetra-
nucleotide repeat polymorphisms, but each institution
uses their own genotyping technology, customized prim-
ers, and controls (see NHLBIMGS and CIDRWeb sites).
Genotyping was done without any knowledge of diag-
nostic status, but family structure information was used
to help detect and resolve genotyping errors.
Classiﬁcation of Subjects for Linkage Analyses
There are two fundamental questions with regard to
the status of each participant in a genetic study of ARM:
(1) How conﬁdent can one be that an individual is
affected with a macular degeneration? (i.e., disease-
severity status) and (2) Given an affected individual, how
conﬁdent can one be of the diagnosis? (i.e., diagnosis
status). Three classiﬁcations were used for the disease-
severity status: deﬁnitely affected, probably affected, and
possibly affected or unaffected. For the diagnosis status,
the following four classiﬁcations were used: ARM,ARM
or another condition, another condition that is not
ARM, and no evidence of ARM (from either photo-
graphs or records). Each subject was classiﬁed for both
disease-severity status and diagnosis status. After all
members of a given family had been evaluated, the entire
family was reviewed for consistency of the diagnostic
criteria and was assessed as to ﬁnal eligibility for the
genomewide genotyping efforts.
We established three clinical grades of ARM for ge-
netic analyses. Under the most stringent model (model
A), individuals were classiﬁed as “affected” only if they
were clearly affected with ARM on the basis of exten-
sive/coalescent drusen, pigmentary changes (including
pigment epithelial detachments), and/or the presence of
endstage disease (geographic atrophy and/or choroidal
neovascular membranes). Model B analyses classiﬁed as
“affected” all those considered affected under model A
and those who were considered to be probably affected
with ARM, on the basis of moderate to extensive soft
drusen, extensive hard drusen with pigmentary changes,
and suspected pigment epithelial detachments. Model C
classiﬁed as “affected” all of those considered affected
under models A and B and those whose diagnosis of
ARM was less clear. Under model C, individuals were
considered affected if they were deﬁnitely and probably
affected with ARM or with a related maculopathy (hav-
ing insufﬁcient evidence to rule out another type of
macular disease). Model C also included individuals
with endstage disease (choroidal neovascular mem-
branes, disciform scarring, and/or geographic atrophy),
in the absence of any other documentation of macular
pathology. These individuals were considered to be def-
initely affected, but the determination of whether the
etiology was ARM or another maculopathy was con-
sidered ambiguous. Our diagnostic models were nested;
for example, individuals considered affected under
modes B and C, but not under model A, were coded as
“unknowns” in the linkage analyses performed with
model A diagnoses.
Families eligible for genomewide scans were required
to have at least two affected individuals. Efforts were
also made to enroll an unaffected informative family
member for comparison. The average size of the families
(including affected, unknown, or unaffected individuals)
ascertained at the Pittsburgh, Duke, and Vanderbilt sites
was 2.58 people. Of 628 families (totaling 1,616 indi-
viduals) submitted for analysis, 1,159 individuals were
deﬁnitely affected with ARM and 261 were probably
affected with ARM. Thus, 75.69% of affected individ-
uals were included within model A, and 92.17% of all
individuals were treated as affected in any of the models
(A, B, or C).
Statistical Analyses: Error Checking
Our genotyping data were subjected to several quality
checks in order to help ensure accurate genotyping. Ge-
notypes at each locus were checked for Mendelian in-
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Table 5










No. of Families Used/





5 198.2 D5S211 B .000 1.801 35/492 59.75 .05 HrL
8 39.2 D8S1145 A .000 3.794 35/482 [22.5, 27.38] .0055 S
10 154.0 D10S1230 A 1.824 3.868 165/482 26.05 .0419 HrL
10 154.0 D10S1230 B 1.832 4.252 161/488 26.05 .0474 HrL
13 29.8 D13S325 A .050 3.905 98/480 [26.50, 49.16] .0092 S
20 56.7 D20S478 A .001 4.633 66/480 [27.75, 43] .0005 S
20 56.7 D20S478 B .017 5.232 64/486 [27.75, 43] !.0001 S
20 56.7 D20S478 C .007 5.655 44/498 [31.50, 43] !.0001 S
a L p low; H p high; S p optimal slice method.
consistencies with the use of our program, PedCheck
(O’Connell and Weeks 1998), which uses genotype elim-
ination to identify the more subtle inconsistencies. We
compared the number of homozygotes observed with
the number of homozygotes expected on the basis of the
estimated allele frequencies; a disparity in these numbers
may indicate the misnaming of heterozygous genotypes
as homozygous. We also examined the genotypes of sev-
eral putative MZ twin pairs to assay the quality of our
genotyping data.
We used the relationship-estimation program PREST
(McPeek and Sun 2000) to check the accuracy of our
assumed relationships between individuals against the
realized level of allele sharing across the whole genome.
This led to the omission of four small families, in which
relationship errors could not be resolved, from our cur-
rent set of families.
Allele Frequency Estimation
We estimated allele frequencies at each locus by simple
allele counting in all individuals (disregarding relation-
ships), within each data set (MGS, CIDR1, and CIDR2)
separately. This approach generates unbiased estimates
when applied to randomly ascertained families (Broman
2001). However, our allele-frequency estimates can be
biased by the fact that the vast majority of our genotypes
occur in affected individuals. Thus, if there were a strong
association of a particular allele occurring more often
in affected individuals than in the general population,
the frequency of that allele would be overestimated. This
potential effect is conservative, in that it would bias us
away from linkage (Ott 1992; Go¨ring and Terwilliger
2000). We found elsewhere (Weeks et al. 2000) that the
use of more precise allele-frequency estimates that take
relationships into account (obtaining these estimates is
computationally time consuming) generated essentially
identical results to those obtained by our simpler (and
much faster) estimation approach.
We used data set–speciﬁc marker-allele frequencies in
all our analyses, because the genotyping centers used
different technologies that resulted in slightly different
allele labels at many loci. Additionally, the technology
used by CIDR to genotype the CIDR2 data set had
changed since they ﬁrst performed genotyping for the
CIDR1 data set. Rather than laboriously attempting to
establish the exact correspondence between every allele
in each of the three data sets, we took a simpler
approach, employing data set–speciﬁc marker-allele
frequencies in all our analyses, especially because the
capabilities of Allegro (Gudbjartsson et al. 2000) had
been extended graciously (at our request) to handle cor-
rectly the data-set–speciﬁc allele frequencies.
Linkage Analysis
We performed the following analyses:
1. Single-point and multipoint LOD scores under het-
erogeneity: Since many of our pedigrees show in-
heritance patterns that seem to be consistent with
dominant inheritance, we chose, a priori, to com-
pute LOD scores under a single simple dominant
model (disease allele frequency p 0.0001; pene-
trance vectorp [0.01 0.90 0.90]) and to allow for
heterogeneity under an admixture model (Hodge et
al. 1983). Only two disease phenotypes were used:
“affected” and “unknown”; no one was given a
“normal” phenotype, owing to the complexities of
the ARM phenotype. The single-point and multi-
point LOD scores were computed by Allegro
(Gudbjartsson et al. 2000) with data set–speciﬁc
marker allele frequencies (as described above).Note
that the majority of our families are so small that
the family-speciﬁc LOD score maximizes at either
or . With a desire to keep the numbervp 0 vp .50
of models used in the analyses as low as possible,
we elected not to employ age-dependent penetrance
models in our study.
2. Single-marker and multipoint “model-free” meth-
ods: We computed single-point and multipoint
“model free” LOD scores, using the Sall statistic
under the linear model with Allegro (Gudbjartsson
184 Am. J. Hum. Genet. 75:174–189, 2004
Table 6










No. of Families Used/





5 101.1 D5S641 C .294 1.386 59/410 [.125, .667] .0295 S
9 8.2 D9S168/D9S921 C .259 2.775 59/406 [.333, .750] .0303 S
18 95.1 D18S1357 A .402 1.178 305/396 .333 .0223 LrH
19 53.7 D19S245 B .258 .972 45/399 .750 .0240 HrL
a L p low; H p high; S p optimal slice method.
et al. 2000). Data set–speciﬁc marker-allele fre-
quencies were used.
3. Power to detect linkage: Although power estimates
for complex diseases may not be very helpful, we
presented simulations elsewhere (Weeks et al. 2000)
that indicated that, if the genetic effect is large
enough, we will have high power to detect linkage.
However, as might be expected, the power depends
strongly on the percentage of families linked to the
region of interest.
4. False-positive rates: We simulated genomewide au-
tosomal marker data, using data set–speciﬁc allele
frequencies, on all the pedigrees for each of the
diagnostic models. To do this, we used Allegro to
simulate marker genotypes for exactly the same
people genotyped and the same disease phenotypes
as in the original real data, under the assumption
that the set of markers was segregating indepen-
dently of ARM disease status. We then analyzed
each simulated replicate, using Allegro in exactly
the same manner in which we had analyzed the real
data, and recorded the results. We used 1,000 rep-
licates to compute the empirical probability of ob-
serving a LOD score greater than or equal to a given
threshold anywhere in the genome.
5. Ordered subsets analysis (OSA): To explore the
relationship of relevant covariates to genetic het-
erogeneity, we applied OSAs, which use quanti-
tative covariates to identify potentially more ho-
mogeneous subgroups from the overall sample
(Hauser and Boehnke 1998; Watanabe et al. 1999;
Ghosh et al. 2000; Hauser et al. 2001, 2004). In
the OSA approach, families are ﬁrst ranked by an
appropriate family-level covariate. Then, families
are added into the calculations one at a time in
rank order, from one extreme to the other. After
each family is added, a maximum LOD score
(MLS) is computed for the current contiguous sub-
set of the families; here we use the nonparametric
LOD score based on the Sall sharing measure, with
data set–speciﬁc allele frequencies. The OSA-LOD
statistic is the largest MLS of all ordered subsets
of the families. Three different OSA-LOD statistics
are obtained—by adding families from lowest to
highest rank, by adding families from highest to
lowest rank, and by ﬁnding the best contiguous
subset (“optimal slice”) with the largest MLS.
We tested whether the best covariate-deﬁned subset
yields a signiﬁcant increase in the LOD score, as com-
pared with what one would obtain with randomly or-
dered families. In other words, the P value measures how
often an OSA-LOD greater than or equal to the observed
OSA-LOD would occur in a subset of the randomly
ranked families, on a chromosomewide basis, given our
family-level LOD scores. Other simulation studies have
shown that this approach has an appropriate type I error
rate and can lead to increased power in the presence of
heterogeneity (Hauser et al. 2001).
The family-level covariates we used were (1) mean age
at onset, (2) mean pack-years, (3) proportion of affecteds
with at least one APOE-2 allele, and (4) proportion of
affecteds with at least one APOE-4 allele. Age at onset
is the earliest age, as reported by the participant, either
at which symptoms were attributed to ARM or at di-
agnosis. If this is not available, then it is the age at the
earliest records/photos. Pack-years are self reported and
are deﬁned as the product of years and packs, where
“packs” is the number of cigarette packs smoked per
day, with 20 cigarettes per pack. Nonsmokers were as-
signed a pack-years value of zero, and cigar and pipe
smokers were assigned missing values. We computed the
family-speciﬁc values, using only the covariate values of
the affected members in each pedigree. Therefore, it is
possible for a family to have different covariate values
under the different diagnostic models if who is affected
differs across diagnostic models. Also, note that the OSA
program only includes families with known covariate
values, so the number of families used varies across co-
variates and diagnostic models.
Results
We have now completed a genome scan on our third set
of families, which, under diagnostic model C, contains
202 families with two or more genotyped affected in-
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Table 7










No. of Families Used/





6 121.1 D6S474 A .000 1.501 38/398 .667 .0120 HrL
7 191.6 D7S559 A .000 1.442 38/396 .667 .0136 HrL
7 186.2 D7S3058 B .000 1.191 37/399 .667 .0145 HrL
7 182.6 D7S3058 C .000 1.505 31/407 .750 .0119 HrL
11 40.3 D11S1392 C .089 .744 87/406 .500 .0261 HrL
15 8.6 D15S165 C .214 1.339 37/407 .667 .0327 HrL
a L p low; H p high; S p optimal slice method.
dividuals and 297 affected sib pairs (table 2). These num-
bers differ slightly from the methodology section, as
some samples failed to be genotyped by the genotyping
centers (primarily owing to inadequate amounts of DNA
or to quality control issues). Our collaborators at Van-
derbilt University contributed 14 of the families con-
taining 27 affected sib pairs (under model C), and our
collaborators at Duke University contributed 41 families
containing 80 affected sib pairs. One could interpret our
new data in two different ways. The ﬁrst approach
would be to treat our current genome scan as an inde-
pendent conﬁrmation set. Our current genome-scan set
is larger than those of our previous genomewide scans
(table 2). The second approach is simply to pool all three
genome scans together. We discuss both of these ap-
proaches below.
Third Scan as Independent Conﬁrmation
If one treats the third genome scan as an independent
replication set, then we can directly address the question
of whether a peak implicated in our earlier work is rep-
licated in our third genome scan. However, because some
of the families used in our earlier studies were expanded
and regenotyped for the third genome scan, this required
that we recompute our results on the ﬁrst two genome
scans after removing these families. This did not alter
our earlier conclusions, based on the combined analyses
of the ﬁrst two genome scans (Weeks et al. 2001), that
four regions (1q31, 9p13, 10q26, and 17q25) all show
multipoint HLOD or Sall scores of 2.0 (under at least
one model). However, when we examine the results on
the third genomewide screen, only two (10q26 and
17q25) of these four regions appear to have been rep-
licated with LOD scores 11.0. In the 10q26 region, we
obtain an Sall of 1.50 at D10S212 under model B (and
an Sall of 1.20 and 1.21 under models A and C, respec-
tively, at or near D10S212). In the 17q25 region, we
obtained an HLOD of 1.20 at D17S784 under model B
(whereas the HLOD reaches a maximum of 0.85 at
D17S784 under model A). When interpreting these re-
sults, it is important to remember that genome scans on
small data sets can show remarkable variability in both
evidence of linkage and location estimates (Cordell
2001).
Pooled Analyses
We computed both single-point and multipoint link-
age statistics (HLOD and Sall) on our combined set of
families; summary descriptions of the numbers of fam-
ilies and numbers of affected relative pairs are provided
in table 2. Table 3 displays those markers that had el-
evated single-point or multipoint statistics 1.5, and
ﬁgure 1 presents the multipoint curves for chromosomes
1, 2, 10, and 17. On chromosome 1, the 1q31 region
had a maximum multipoint HLOD of 2.72 at D1S1660
under model C; the corresponding genomewide empir-
ical . Elevated HLOD peaks were also seenPp .061
under models A and B (ﬁg. 1). On chromosome 2q14.3,
under model A, there is a signiﬁcant single-point Sall
of 3.23 (marginal single-point empirical ) atPp .0
D2S1328 (table 2) and a multipoint Sall of 2.42 (ge-
nomewide empirical ) at the same location (ﬁg.Pp .12
1). Under model B, the single-point Sall at D2S1328 is
2.18, but the multipoint curve reaches a maximum of
only 1.35, whereas there is no linkage signal under
model C. On chromosome 10q26, a multipoint Sall peak
is seen consistently across all three models, with a max-
imum Sall of 2.69 (genomewide empirical ) atPp .06
D10S1230 under model C. The 17q25 region contains
our highest LOD score, with elevated HLODs across all
three models and a maximum multipoint HLOD of 3.53
between D17S784 and D17S928 under model B (ﬁg. 1).
The genomewide empirical P value for an HLODof 3.53
is .007.
On the basis of our simulation study, the genomewide
empirical P value for a multipoint LOD score (either Sall
or HLOD) of 3.0 is in the range of .03 to .04. For a
multipoint LOD score of 2.5, the genomewide empirical
P value is in the range of .09 to .11. Note that HLOD
and Sall have approximately the same null distribution,
since both involve estimating two free parameters—for
HLOD, one maximizes across location and a (where a
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is the fraction of linked families); for Sall, one maximizes
across location and d (see Kong and Cox [1997] for a
deﬁnition of d). The genomewide empirical P value mea-
sures the chance of seeing a LOD score greater than or
equal to the threshold anywhere in the genome and, thus,
is larger than the marginal P value evaluated at a single
point in the genome.
Exploration of Covariate Effects
The formation of subsets on the basis of relevant co-
variates with the OSA approach, although exploratory
in nature, may result in more genetically homogenous
subsets. Tables 4, 5, 6, and 7 present our results after
we formed subsets on the basis of (1) mean age at onset,
(2) mean pack-years, (3) proportion of affecteds with at
least one APOE-2 allele, and (4) proportion of affecteds
with at least one APOE-4 allele. With regard to the
regions on chromosomes 1, 2, 10, and 17 implicated by
the conventional linkage analyses described above, only
the 10q26 region has interesting OSA-LODs (table 5).
Under both models A and B, the OSAs reveal a subgroup
of ∼160 highest smoking (mean pack-years 26) fam-
ilies, with elevated OSA-LODs of 3.87 and 4.25,
respectively.
With the use of mean pack-years, the optimal slice
method generates large OSA-LODs between 4.63 and
5.66, under all three models, on chromosome 20 near
D20S478 (table 5). Under models B and C, the per-
mutation-based P value is quite small, and the optimal
slice includes families with ∼27–43 mean pack-years.
When we stratify on the proportion of affecteds with
at least one APOE-2 allele or on the proportion with at
least one APOE-4 allele, only modest OSA-LODs are
observed (tables 6 and 7). For APOE-4, however, we do
observe, across all three diagnostic models, elevatedOSA-
LODs in the same region on chromosome 7 (table 7).
Discussion
It is difﬁcult to study the genetics of ARM because the
disease has a late age at onset, which implies that the
parents are usually not available for genotyping. Fur-
thermore, the incidence of ARM increases rapidly with
advancing age, suggesting that the probability that an
affected individual is a nongenetic phenocopy also in-
creases rapidly with age. Given these potential difﬁcul-
ties, we ﬁnd it heartening and encouraging that some
regions of the genome have been implicated by multiple
studies.
First, if we treat our current genome scan as an in-
dependent replication set, then two of our four previ-
ously implicated regions, 10q26 and 17q25, are repli-
cated. Second, if we pool all three of our genome scans
together, then the regions of interest are 1q31, 2q14.3,
10q26, and 17q25. As detailed in the introduction, both
the 1q31 and 10q26 regions have been found in other
studies (see table 1). In addition to being implicated by
our studies, the 1q25–31 region has been implicated by
ﬁve other studies (Klein et al. 1998; Majewski et al.
2003; Seddon et al. 2003; Abecasis et al. 2004; Iyengar
et al. 2004). Furthermore, a mutation in the HEMI-
CENTIN-1 gene has been found that segregates with
the disease in the initial large family (Schultz et al.
2003a, 2003c). Similarly, the 10q26 peak has been sup-
ported consistently across all three of our studies (even
when the third scan is considered by itself alone), and
Majewski et al. (2003) found their strongest evidence
of linkage in this region. Furthermore, as detailed in the
introduction, this region has been supported by three
other studies (Seddon et al. 2003; Iyengar et al. 2004;
Kenealy et al. 2004).
Our identiﬁed regions of interest, based on an affect-
eds-only analysis, do not appear to overlap with those
of Schick et al. (2003), who analyzed a quantitative
measure of ARM. Their best peak was in the 12q23–
24 region, which is ∼20 cM from a minor Sall peak of
1.63 at D12S2070; since their reported peak is wide,
this result could constitute an overlap.
The OSA approach represents exploratory data anal-
ysis, and, as such, serves mainly as a way to use our
data to generate new hypotheses that must be tested in
independent data sets. One interesting hypothesis, gen-
erated by our OSA results (tables 4, 5, 6, and 7), is that
the effect of smoking on risk of ARM is accentuated by
a gene in the chromosome 10q26 region. That is, OSAs
found a stronger linkage signal in the subgroup of fam-
ilies with high levels of smoking among the affected
individuals. This is particularly intriguing—ﬁrst, be-
cause the 10q26 region has been implicated by multiple
studies and, second, because there is ample evidence that
smoking markedly increases the risk of ARM (Klein et
al. 1993; Schwartz 1994; Seddon et al. 1996; Vingerling
et al. 1996; Klaver et al. 1997; Tamakoshi et al. 1997;
Delcourt et al. 1998).
Our most signiﬁcant OSA result occurs on chromo-
some 20 (table 5) near D20S481, with the use of the
“optimal slice” method. Although the permutation re-
sults indicate that to observe a subgroup with such a
large OSA-LOD by chance is extremely unlikely, this
result still must be viewed with caution, since it suggests
the unlikely hypothesis that smoking has a U-shaped
effect on disease risk; for example, families with 27–43
mean pack-years are linked, whereas families with smok-
ing levels below and above this range are not linked.
In summary, we have performed careful linkage anal-
yses on the largest set of families with ARM assembled
to date and have found continued support for the 1q31,
10q26, and 17q25 regions. Two of these regions, 1q31
and 10q26, have also been identiﬁed in several other
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independent studies. This remarkable consistency be-
tween studies is very encouraging and argues in favor
of these regions containing true susceptibility genes for
ARM. Finally, the exploratory OSAs generate the in-
teresting hypothesis that the effect of smoking on risk
of ARM is accentuated by a gene in the 10q26 region.
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